Adlai Nortye Ltd

NASDAQ:ANLUnited States

Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates. AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment. AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025.

Contact Information

Headquarters

c/o Ugland House PO Box 309GRAND CAYMAN, NJ, Cayman Islands KY1-1104

Phone

848-230-7430

Fax

---

Executives

Chairman of the Board, Chief Executive Officer

Yang Lu

President, Director Nominee, Chief Medical Officer, Chief Executive Officer of U.S. Subsidiary

Lars Birgerson

Chief Financial Officer

Wei Zhang

Senior Vice President, Global Head of Regulatory Affairs

Victoria Demby

Senior Vice President, Global Head of Clinical Operations

Kaiyang Tang